<DOC>
	<DOCNO>NCT01479764</DOCNO>
	<brief_summary>This study compare incidence residual neuromuscular blockade participant undergo reversal neuromuscular blockade sugammadex compare undergo reversal neuromuscular blockade usual care ( neostigmine/glycopyrrolate ) .</brief_summary>
	<brief_title>Study Sugammadex Versus Usual Care Incidence Residual Blockade Post Anesthesia Care Unit Admission ( P07981 )</brief_title>
	<detailed_description />
	<mesh_term>Neostigmine</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>American Society Anesthesiologists ( ASA ) Class 1 2 3 Scheduled undergo elective abdominal surgical procedure general anesthesia ; : expect undergo neuromuscular relaxation rocuronium endotracheal intubation ; expect require least one maintenance dose rocuronium ; expect require active reversal neuromuscular blockade ; expect require clinical subjective neuromuscular monitoring ; expect recover PACU Arm accessible measure TOF ratio PACU Sexually active female patient childbearing potential must agree use medically accept method contraception seven day receive protocolspecified medication . Anatomical malformation may lead difficult intubation Neuromuscular disorder ( ) may affect neuromuscular blockade and/or trial assessment Dialysisdependent suspect severe renal insufficiency Significant hepatic dysfunction Family history malignant hyperthermia Cardiac pacemaker Allergy study treatment its/their excipients , opioids / opiate , sugammadex , muscle relaxant excipients , medication ( ) use general anesthesia Toremifene within 24 hour study drug administration Scheduled overnight stay ( &gt; 12 hour ) PACU Expected transfer Intensive Care Unit surgery Pregnant , intention become pregnant randomization Day 30 pregnancy followup visit Breastfeeding . Investigational drug ( ) within 30 day randomization study Participation clinical trial within 30 day , inclusive , sign informed consent form current trial Participant family member among personnel investigational Sponsor staff directly involve trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>